Nuvaira Announces 1st Patient Treated in RELIEF-1 Study Evaluating New Approach for Asthma Treatment
Clinical Trial Assesses First-of-its-Kind, One-Time Medical Procedure in Patients with Severe Asthma
MINNEAPOLIS, March 27, 2018 (GLOBE NEWSWIRE) -- Nuvaira, a developer of medical devices to treat obstructive lung diseases, today announced treatment of the first patient in the RELIEF-1 Clinical Study in Europe. The RELIEF-1 trial (NCT02872298) is a prospective, multi-center, single-arm (non-randomized) study designed to evaluate the safety and technical feasibility of a procedure called Targeted Lung Denervation (TLD) using the Nuvaira(TM) Lung Denervation System for the treatment of severe asthma.
The feasibility study is slated to treat a total of 30 patients at facilities in France, Germany, the Netherlands and the United Kingdom, with patient follow-up planned out to three years. Principal Investigators of RELIEF-1 are Nick ten Hacken, M.D., Ph.D., at the University Medical Center Groningen (UMCG), the Netherlands, and Professor Pallav Shah, M.D., at Royal Brompton & Harefield NHS Foundation Trust and Chelsea and Westminster Hospital NHS Foundation Trust in London. Dirk-Jan Slebos, M.D., Ph.D., performed the first patient treatment in the Department of Pulmonary Diseases at UMCG.
"The first patient tolerated the minimally invasive therapeutic treatment very well and there were no procedural complications," according to Dr. ten Hacken. "TLD is the first medical procedure that targets the whole lung by disrupting the overactive nerves into the lungs, thereby opening up the airways and making it easier to breathe. We are encouraged by how well the first patient responded to TLD and we look forward to treating additional asthma patients utilizing this innovative, one-time procedure."
The Nuvaira Lung Denervation System is a catheter-based system developed to treat patients with obstructive lung disease, specifically severe asthma and chronic obstructive pulmonary disease (COPD). The system's proprietary technology delivers targeted energy to disrupt nerve signals to the lungs using a process known as denervation. The simple, one-time bronchoscopic treatment has the potential to provide lasting whole lung improvement for severe asthma patients by opening obstructed airways to make breathing easier. Currently, there is no cure for asthma, but there are treatment plans that can help patients manage the disease. Approximately three quarters of asthma sufferers are adults, with 10 percent suffering from severe asthma, which is difficult to treat.
"The first patient treatment in our RELIEF-1 Clinical Trial is an important milestone in our quest to develop a safe and effective treatment for asthma patients worldwide," said Dennis Wahr, M.D., chief executive officer at Nuvaira. "Earlier trials evaluating TLD in COPD patients have demonstrated feasibility and promising long-term, sustained treatment results. We look forward to the completion of this important study."
Asthma is among the most prevalent chronic respiratory diseases, estimated to affect over 300 million people globally. Asthma sufferers have difficulty moving air in and out of the lungs, due to airway narrowing (bronchoconstriction), airway wall thickening (inflammation), and elevated mucus production. The ongoing burden of this serious and costly disease is estimated at more than $50 billion per year with more than 5,000 emergency department visits per day in the US alone,. Severe asthma often requires multiple medications to maintain or achieve control of symptoms and the risk of flare-ups. Severe asthma may also be refractory, or insensitive to currently available medications. This means that despite use of their medications, these patients still cannot achieve asthma control or avoid flare-ups, which may result in an overall reduction in their quality of life.
Nuvaira (formerly known as Holaira) is a privately held company headquartered in Minneapolis, Minn. The company is developing the Nuvaira(TM) Lung Denervation System to address chronic obstructive pulmonary disease (COPD) and asthma by treating the overactive airway nerves during Targeted Lung Denervation* (TLD). Nuvaira received CE Mark approval for its Nuvaira Lung Denervation System for the treatment of COPD in January 2016. More information may be found at www.Nuvaira.com.
*Targeted Lung Denervation (TLD) is currently under clinical investigation for asthma and COPD and is not yet commercially available.
Nuvaira is a trademark of Nuvaira, Inc.
 G John Gibson, Robert Leddenkemper, Yves Sibille, Bo Lundback. European Lung White Book: Respiratory Health and Disease in Europe. European Respiratory Society, 2013.
 Global, regional prevalence for COPD and asthma 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. www.the lancert.com/respiratory. Online Aug. 16, 2017.
 Wang, Emergency department charges for asthma-related outpatient visits. J Health Care Poor Underserved. 2014 February; 25(1):396-405
 Barnett, Costs of Asthma in the United States:2002-2007. J Allergy Clin Immunol January 2011.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b9fcef4f-e7c0-44d9-8bae-fed2aa8b1c66
Media Inquiries: Amy Wolter +1 (763) 450-5676 firstname.lastname@example.org
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nuvaira, Inc via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Raising Internal Awareness About GDPR is Main Challenge, Say Subscription Businesses25.4.2018 20:00 | Pressmeddelande
WARRINGTON, United Kingdom, April 25, 2018 (GLOBE NEWSWIRE) -- With the countdown to the arrival of GDPR reaching the critical stages, more than a third of subscription businesses say that their biggest remaining challenge is raising internal awareness and knowledge about the legislation. GDPR comes into force May 25, with major implications for subscription businesses that collect personal data from B2B or B2C customers located in the EU. MPP Global hosted two recent webinars, focusing on the roles of data processor and data controller, to help businesses understand their responsibilities under the new regulations. Research conducted during these webinars uncovered that the main challenge identified by 34 percent of attendees ahead of GDPR was ensuring that their colleagues were aware of the changes in legislation and the potential implications of a breach. "These findings show that there is still some work to be done around GDPR," said MPP Global CEO and Co-Founder Paul Johnson. "GDP
PowerPlan Named Finalist for 2018 SAP® Pinnacle Award25.4.2018 16:10 | Pressmeddelande
ATLANTA, April 25, 2018 (GLOBE NEWSWIRE) -- PowerPlan is pleased to announce that SAP has recognized it as a finalist for an SAP® Pinnacle Award in the ISV Partner of the Year - Technology Innovation Award category. The annual SAP Pinnacle Awards acknowledge the contributions of leading SAP partners that have excelled in developing and growing their partnership with SAP and helping customers meet their goals. Finalists and winners in 29 categories were chosen based on recommendations from the SAP field, customer feedback and performance indicators. "We're honored to be recognized by SAP. Our distinction as a finalist highlights that the visions of PowerPlan and SAP continue to align," said Brent Burns, COO, PowerPlan. PowerPlan has been an OEM partner for SAP since June 2017. The introduction of the PowerPlan Adapter for SAP S4/HANA gained popularity due to its advanced cloud functionality and user-friendly interface. "Working with SAP has enabled our clients to run simple, yet strateg
Appian Announces 2018 Global and Regional Partners of the Year25.4.2018 15:01 | Pressmeddelande
RESTON, Va., April 25, 2018 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announced its 2018 Global and Regional Partners of the Year winners. These strategic partners were selected based on their success in helping companies develop and execute digital transformation initiatives using Appian's low-code platform. Appian's partner ecosystem is consists of organizations that provide world-class solutions and services globally across a variety of industries. Global and Regional Partner of the Year Winners: Global Partner of the Year - KPMG Regional Partner of the Year, Europe - PwC Regional Partner of the Year, APAC - Incessant Regional Partner of the Year (Mid-Market) - Bits In Glass Global Trusted Program: Partner of the Year - Vuram "Our recognition as Appian's Global Partner of the Year for the third consecutive year demonstrates the strength of our combined business and technology leadership," said Jerry Iacouzzi, U.S. leader for digital enablement at KPMG. "Digital transformation i
LeoVegas kommentar på information gällande ändrade förutsättningar på den norska marknaden25.4.2018 14:32 | Pressmeddelande
I LeoVegas finansiella mål om intäkter på minst 600 MEUR år 2020 och minst 100 MEUR i EBITDA år 2020, som presenterades 19 april, har det tagits i beaktning att marknadsförutsättningar kan förändras. Meddelandet igår om förslaget till norska stortinget är ett exempel på ändrade förutsättningar som LeoVegas strategiska planering tagit höjd för. LeoVegas strävar efter att vara ett transparent bolag och väljer därför att ange storleken på den norska marknaden för att ge en ökad förståelse. I mars 2018 stod den norska marknaden för 4,6% av koncernens totala intäkter. Oavsett utgång påverkar utvecklingen i Norge inte LeoVegas finansiella mål. "Ännu finns det inga detaljer kring förslaget men i alla branscher får man räkna med att förutsättningarna kan ändras. Vissa marknader stängs ner och andra öppnas och regleras. Norge har idag inget lokalt licenssystem och istället för förbud hoppas jag att Norge rör sig mot en lokal reglering likt den utvecklingen vi ser i Sverige.", säger Gustaf Hagma
LeoVegas comments on information regarding the potential for changing circumstances in the Norwegian market25.4.2018 14:32 | Pressmeddelande
In LeoVegas financial targets of at least EUR 600 million in revenue in 2020 and at least EUR 100 million in EBITDA in 2020, that were presented on April 19th, it has been taken into account that market conditions can change. The announcement yesterday about the proposal in the Norwegian Parliament is an example of changing conditions that LeoVegas' strategic planning has made room for. LeoVegas strives to be a transparent company and therefore chooses to disclose the size of the Norwegian market in order to increase understanding of the potential impact. In March 2018, the Norwegian market accounted for 4.6% of LeoVegas total revenues. Regardless of the outcome the development in Norway, it does not affect LeoVegas financial targets. "There are still no details about the proposal, but in all industries, one can expect that the conditions can change. Some markets are closed and others are opened and regulated. Norway currently has no local licensing system, and instead of prohibition,
Gemini to Launch Market Surveillance Technology in Collaboration with Nasdaq25.4.2018 12:30 | Pressmeddelande
Nasdaq is providing SMARTS Market Surveillance technology to monitor cryptocurrency market NEW YORK and STOCKHOLM, Sweden, April 25, 2018 (GLOBE NEWSWIRE) -- Gemini Trust Company, LLC (Gemini) and Nasdaq Inc. (Nasdaq:NDAQ) announced today that Gemini will be leveraging Nasdaq's SMARTS Market Surveillance technology to monitor its marketplace. The technology, which is considered the most widely deployed surveillance system in the world, will enable Gemini to monitor across all of its trading pairs, including: BTC/USD, ETH/USD and BTC/ETH. Further, SMARTS will also surveil activity across the Gemini auction process that is used to determine the settlement price for the Bitcoin XBT futures contracts that trade on Cboe's CFE Exchange. "Since launch, Gemini has aggressively pursued comprehensive compliance and surveillance programs, which we believe betters our exchange and the cryptocurrency industry as a whole," said Tyler Winklevoss, CEO, Gemini. "Our deployment of Nasdaq's SMARTS Market
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum